Metagenomi closes oversubscribed $175M Series B financing

US gene editing start-up Metagenomi has announced the completion of an up-sized and oversubscribed $175 million Series B financing.

This brings the total amount of funding for the company to $300 million. Proceeds from the financing will be used to advance Metagenomi’s lead in vivo and ex vivo gene editing therapeutic programs through pre-clinical development and into the clinic. This will include expansion of its manufacturing, automation and AI infrastructure, and further development of the company’s differentiated toolbox of next-generation gene editing systems.

“Our expertise in mining the world’s natural environments for novel gene editing systems has resulted in the discovery of a powerful suite of gene editing tools,” said Brian Thomas, co-founder and chief executive of Metagenomi. “We are honored to be supported by an impressive group of investors who understand the enormous potential of our gene editing capabilities. We look forward to the next phase of the Company’s development as we accelerate our lead gene editing programs, and open new treatment options in metabolic, cardiovascular, and CNS diseases, as well as in immuno-oncology,” he added.